Using PSURs for Benefit-Risk Evaluation in Pharmacovigilance

Periodic Safety Update Reports (PSURs) are critical tools for assessing the benefit-risk balance of a pharmaceutical product during its post-marketing lifecycle. They serve not only to report cumulative safety data but also to contextualize these findings against the known benefits of the drug. A well-prepared PSUR enables sponsors and regulators to make informed decisions about product labeling, continued marketing, or necessary risk mitigation strategies. This guide explains how to effectively use PSURs for benefit-risk evaluation in compliance with global regulatory expectations.

What is Benefit-Risk Evaluation?

Benefit-risk evaluation is a core function of pharmacovigilance that compares the therapeutic benefits of a drug to its associated risks. These assessments are dynamic and evolve over time with new clinical data, adverse event reports, and real-world usage.

As per the EMA, the benefit-risk assessment is central to determining whether a drug’s market authorization should be maintained, modified, or withdrawn. PSURs are the structured vehicles through which this assessment is regularly updated and communicated.

How PSURs Enable Benefit-Risk Assessments

The PSUR provides a systematic framework to integrate:

• New and cumulative adverse event data
• Post-marketing clinical studies
• Updated exposure estimates
• Labeling changes and regulatory decisions
• Comparative safety data vs similar products

Through this integration, sponsors and regulators can objectively reassess the balance between the benefits and risks of a product.

Relevant Sections of PSUR for Benefit-Risk Evaluation

1. Section 6: Summary of Safety Concerns
2. Section 7: Signal Evaluation
3. Section 8: Integrated Benefit-Risk Analysis
4. Section 9: Conclusions and Actions

These sections must align in content and tone. For example, new signals in Section 7 should be reflected in the updated benefit-risk analysis in Section 8, along with justifications for any proposed changes to the risk management plan (RMP).

Quantitative and Qualitative Approaches

Benefit-risk evaluations can be presented in two main formats:

1. Qualitative Assessment

• Uses expert medical judgment
• Describes how reported risks affect the overall safety profile
• Justifies whether the risk alters the favorable benefit-risk balance

2. Quantitative Models

• Applies statistical models such as Number Needed to Treat (NNT) and Number Needed to Harm (NNH)
• Used for chronic or high-risk products where risk is harder to interpret qualitatively
• Visual tools like benefit-risk grids, value trees, and forest plots

These tools can be implemented using software approved under validation master plans to ensure audit-ready outputs.

Incorporating Real-World Data in Benefit-Risk Analysis

PSURs should not rely solely on clinical trial results. They must integrate real-world data (RWD), including:

• Spontaneous AE reporting
• Product usage trends
• Off-label usage reports
• Stability testing results indicating quality-linked safety issues
• Patient feedback and compliance patterns

This multi-dimensional approach offers a richer, more realistic picture of benefit-risk balance.

Case Example: Benefit-Risk Reevaluation in Antidiabetics

Imagine a company marketing a novel antidiabetic agent detects an increased frequency of pancreatitis reports. In the latest PSUR:

• The company identifies the signal under Section 7
• Reviews severity, causality, and reversibility of the AE
• Compares data with similar agents on the market
• Updates Section 8 to reflect a slight reduction in the benefit-risk balance
• Proposes a label update and monitoring guideline in Section 9

Such integration demonstrates proactive pharmacovigilance and aligns with GMP compliance.

Best Practices for Benefit-Risk Evaluation in PSURs

• Ensure consistency between safety signal evaluations and benefit-risk narrative
• Use tabular presentations to summarize key risks and corresponding benefits
• Highlight any changes from the previous PSUR cycle
• Justify retention or modification of labeling, RMP, or product status
• Document internal benefit-risk decisions using SOP-compliant formats

Common Pitfalls to Avoid

• Over-reliance on clinical trial data and neglecting real-world signals
• Failure to address newly emerging risks in context of benefits
• Inconsistencies between different PSUR sections
• Unjustified conclusions lacking signal analysis depth

Regulatory Expectations

• EMA: Emphasizes integrated and transparent benefit-risk summaries
• USFDA: Expects direct linkage between signals and risk mitigation plans
• CDSCO: Requires benefit-risk narratives to justify product continuation

Failure to address benefit-risk thoroughly can delay PSUR acceptance or trigger additional post-marketing commitments.

Conclusion

Benefit-risk evaluation within a PSUR is not a checkbox task—it is a central pillar of ongoing pharmacovigilance. A structured, evidence-based benefit-risk section demonstrates a sponsor’s commitment to patient safety and regulatory transparency. By combining medical expertise with statistical tools, real-world data, and a consistent narrative, PSURs can effectively convey the evolving safety landscape of a product and support sound regulatory decision-making.